Jefferies raised the firm’s price target on Eli Lilly (LLY) to $853 from $814 and keeps a Buy rating on the shares. Orforglipron is vital to Lilly’s GLP-1 strategy, and “one of the few meaningful ways” that its obesity portfolio differentiates from Novo Nordisk (NVO), says the analyst, who is “getting more bullish on Orfo’s safety.” The firm models about $14B in risk-adjusted peak sales for orfo, versus the $11B consensus forecast, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY: